Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Publication of GT200500042ApublicationCriticalpatent/GT200500042A/en
LA PRESENTE INVENCION SE REFIERE A COMPUESTOS HEREROARIL Y FENILFULFAMOILO SUSTITUIDOS, A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN TALES COMPUESTO Y AL USO DE TALES COMPUESTOS COMO AGONISTAS DEL RECEPTOR ACTIVADOR DEL PROLIFERADOR DE PEROXISOMA (PPAR). LOS ACTIVADORES DE PPAR ALFA, COMPOSICIONES FARMACEUTICAS QEU CONTIENEN DICHOS COMPUESTOS Y EL USO DE DICHOS COMPUESTOS PARA ELEVAR CIERTOS NIVELES DE LIPIDOS DE PLASMA, INCLUYENDO EL COLESTEROL DE LIPOPROTEINAS DE ALTA DENSIDAD Y PARA DISMINUIR OTROS CIERTOS NIVELES DE LIPIDOS EN PLASMA, TALES COMO COLESTEROLLDL Y TIGLICERIDOS Y POR CONSIGUIENTE PARA TRATAR ENFERMEDADES QUE SE AGRAVAN POR BAJOS NIVELES DE COLESTEROLHDL Y/O ALTOS NIVELES DE COLESTEROLLDL Y TRIGLICERIDOS, TALES COMO ATEROSCLEROSIS Y ENFERMEDADES CARDIOVASCULARERS, EN MAMIFEROS, INCLUYENDO SERES HUMANOS. LOS COMPUESTOS TAMBIEN SON UTILES PAR EL TRATAMIENTO DEL BALANCE ENERGETICO NEGATIVO (NEB) Y ENFERMEDADES ASOCIADAS EN RUMIANTES. T2005THIS INVENTION REFERS TO HEREROARILE AND PHENYLFULFAMOIL SUBSTITUTED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS AND THE USE OF SUCH COMPOUNDS AS AGONISTS OF THE PEROXISOM PROLIFERATOR ACTIVATOR RECEIVER (PPAR). PPAR ALFA ACTIVATORS, PHE PHARMACEUTICAL COMPOSITIONS CONTAIN THESE COMPOUNDS AND THE USE OF SUCH COMPOUNDS TO RAISE CERTAIN LEVELS OF PLASMA LIPIDS, INCLUDING HIGH DENSITY LIPOPROTEIN CHOLESTEROL AND FOR DISTRIBUTES IN COLES TIGLICERIDS AND THEREFORE TO TREAT DISEASES AGGRAVATED BY LOW LEVELS OF CHOLESTEROLHDL AND / OR HIGH LEVELS OF CHOLESTEROLLDL AND TRIGLICERIDES, SUCH AS ATEROSCLEROSIS AND CARDIOVASCULAROS DISEASES, IN MUMMERS. THE COMPOUNDS ARE ALSO USEFUL FOR THE TREATMENT OF THE NEGATIVE ENERGY BALANCE (NEB) AND ASSOCIATED DISEASES IN RUMINANTS. T2005
GT200500042A2004-03-102005-03-09
HETEROARIL- AND PHENYLSULFAMOIL SUBSTITUTED COMPOUNDS
GT200500042A
(en)
Compounds derived from substituted amides, inhibitors of btk activity; pharmaceutical composition comprising them; Useful in the treatment of cancer, bone disorders, autoimmune diseases, among others
Compounds derived from 4-benzylamino-1-carboxyacyl-pyridine, cetp inhibitors; pharmaceutical composition comprising them; pharmaceutical combination; and use in the treatment of metabolic, atherosclerosis and cardiovascular diseases, among others.
Compounds derived from imidazopyrimidine, substituted, pde10a inhibitors; preparation procedure; pharmaceutical composition; and its use for the treatment or prevention of psychotic disorders, schizophrenia, parkinson's disease, multiple sclerosis, among others.
Compounds derived from pyrazolo [3,4-d] pyrimidine, btk inhibitors; and use in the treatment of cancer, autoimmune diseases, mastocytosis, osteoporosis, among others.
Compounds derived from optionally substituted pyrimidinones; pharmaceutical composition that includes them; and its use as phosphodiesterase 1 (pde1) inhibitors for the treatment of diseases involving disorders of the intracellular trajectory of the dopamine d1 receptor such as parkinson's, Alzheimer's, depression, bipolar disease, hypertension, glaucoma.
Specific compounds 2- (3-amino-1- (2,4-difluorophenyl) -1h-1,2,4-triazol-5-yl) -n-methyl-4,5-dihydrobenzene (b) thiene (2, 3-d) oxepin-8-carboxamide, inhibitor of activity of p13 kinase; pharmaceutical composition comprising it; pharmaceutical kit that includes the composition, and its use for the treatment or prophylaxis of cancer.
Compounds derived from phenylamino-isonicotinamide; mek inhibitors; Pharmaceutical composition and use for the treatment of hyperproliferative diseases such as cancer and inflammation.
Compounds derived from narcyclasin and pancratistatin; preparation procedure; pharmaceutical composition; pharmaceutical combination; and its use for the treatment of cancer.